期刊文献+

阿帕替尼治疗老年性胃癌的安全性分析

Safety analysis of apatinib in treatment of senile gastric cancer
下载PDF
导出
摘要 目的:探讨阿帕替尼治疗老年性胃癌的临床疗效及不良反应,以期为老年性胃癌的临床诊治提供参考依据。方法:选择某院收治的32例老年性胃癌患者,随机分为观察组和对照组,每组各16例,对照组给予阿帕替尼模拟片治疗,观察组给予阿帕替尼治疗。比较2组患者的临床疗效,并观察阿帕替尼药物治疗的不良反应发生率。结果:观察组患者部分缓解(PR)、病情稳定(SD)、病情进展(PD)及疾病控制率(DCR)均优于对照组,差异有统计学意义(P<0.05);阿帕替尼的不良反应主要有高血压、蛋白尿、骨髓抑制,其中高血压的发生率为50.0%,骨髓抑制的发生率为43.8%,蛋白尿的发生率为37.5%。结论:阿帕替尼可有效控制老年性胃癌病情,不良反应可耐受,值得临床推广应用。 Objective :To analyze the clinical efficacy and adverse reactions of apatinib in treatment of senile gastric canceRso as to provide reference foRclinical diagnosis and treatment. Methods :32 patients with senile gastric canceRadmitted to hospital were randomly divided into two groups,each with 16 cases.The 16 patients in the control group were treated with simulated tablets of apatinib,while those in the observation group were treated with apatinib.The clinical efficacy of the two groups of patients was compared and the incidence of adverse reactions treated with apatinib was observed. Results :The PR,SD,PD and DCRof the observation group were betteRthan those of the control group,the difference being statistically significant( P <0.05).The adverse reactions of apatinib mainly include hypertension, proteinuria and myelosuppression (50.0%, 43.8%, 37.5% respectively). Conclusion :Apatinib can effectively control the condition of senile gastric cancer, and the adverse reactions can be tolerated. It is worthy of clinical application.
作者 李露 钟春生 LI Lu;ZHONG Chun-sheng(Department of Oncology,Bengbu No.3 People'sHospital,Anhui 233000,China)
出处 《淮海医药》 CAS 2019年第3期244-246,共3页 Journal of Huaihai Medicine
关键词 胃肿瘤 阿帕替尼 不良反应 老年人 Gastric cancer Apatinib Adverse reaction Senile
  • 相关文献

参考文献5

二级参考文献62

  • 1刘淑英,王晓稼.贝伐单抗在肿瘤治疗中相关毒副反应[J].肿瘤学杂志,2009,15(12):1133-1135. 被引量:3
  • 2胡大一,刘梅林,郭艺芳.老年高血压的诊断与治疗中国专家共识(2011版)[J].中国医学前沿杂志(电子版),2012,4(2):31-39. 被引量:101
  • 3全国肿瘤登记中心.中国肿瘤登记工作指导手册[M].北京:中国协和医科大学出版社,2004.48-50.
  • 4赫捷,赵平,陈万青.2012年中国肿瘤登记年报[M].北京:军事医学科学出版社,2012.56-59.
  • 5Curado MPEB,Shin HR,Storm H,et al. Cancer Inci- dence in Five Continents,Vol. IX [M] . Lyon: IARC Sci- entific Publication,2008. 1-837.
  • 6Felay L, Burkhard C,Whe|an S,et al. Cheek and Conver- sion Programs for Cancer Registries. IARC Technical Re- port No.42[M]. Lyon : IARC, 2005.
  • 7Bray F,Parkin DM. Evaluation of data quality in the can- cer registry:principles and methods. Part I :comparabili- ty, validity and timeliness [J]. Eur J Cancer, 2009,45 (5).. 747-755.
  • 8Parkin DM,Chen VW,Ferlay J,et al. Comparability and Quality Control in Cancer Registration. |ARC Technical Report No.19[M]. Lyon:|ARC, 1994-.
  • 9Felay J. The IARCcrgTools program[EB/OL], http://www.i- acr.com.fr/iarccrgtoo|s.htm.
  • 10Allemani C,Weir HK,Carrira H,et al. Global surveil- lance of cancer survival 1995-2009 :analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)[J]. Lancet,2014, Nov 26.[Epub ahead of print].

共引文献1299

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部